L4 ANSWER 1 OF 7 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 1994:532148 BIOSIS
DN PREV199497545148
TI Mutation of p53 gene in human **cancers** of the esophagus and gastric cardia.
AU Li, Huan-Chuan; Lu, Shi-Xin
CS Cancer Inst., Chinese Academy Med. Sci. Peking Union Med. College, Beijing 100021 China
SO Zhonghua Zhongliu Zazhi (1994) Vol. 16, No. 3, pp. 172-176.
ISSN: 0253-3758.
DT Article
LA Chinese
SL Chinese; English
AB p53 gene in human esophageal **cancer** (EC) and **cancer** of gastric cardia was analyzed. Southern blotting hybridization revealed that five of 35 of EC sample were found to contain abnormal structure of **p63** gene, including 2 deletions and 3 rearrangements; two of 27 adjacent non-tumor tissues also contain abnormal structure of p53 gene (7.4%), among them one case was fragment deletion and another case was rearrangement. PCR-direct sequencing technique was used to detect p53 point mutation within exon and intron 5 through 9. Fifteen of 30(50%) of esophageal squamous cell carcinomas contained mutation of p53 gene. Five of 11(45%) adjacent non-tumor tissues also contained mutation of p53 gene. An esophageal adenocarcinoma shoved p53 mutation. Three of 4 carcinoma of gastric cardia showed p53 mutation. Mutation spectrum in EC: 8 OF 22 cases (36.4%) of p53 mutation were G:C to A:T transition, 6 of 22 cases (27.3%) of p53 mutation were frameshift mutation, including 13.6% (3/22) insertion and 9.1% (2/22) deletion mutation. Some new sites of p53 mutation in human EC were identified. The results suggest that the p53 gene plays an important role in carcinogenesis of human esophagus and gastric cardia.
CC Cytology and Cytochemistry - Human *02508
Genetics and Cytogenetics - Human *03508
Clinical Biochemistry; General Methods and Applications *10006
Biochemical Studies - Nucleic Acids, Purines and Pyrimidines 10062
Biochemical Studies - Proteins, Peptides and Amino Acids 10064
Digestive System - Pathology *14006
Blood, Blood-Forming Organs and Body Fluids - Blood Cell Studies *15004
Neoplasms and Neoplastic Agents - Biochemistry *24006
Neoplasms and Neoplastic Agents - Carcinogens and Carcinogenesis *24007
BC Hominidae *86215
IT Major Concepts
Blood and Lymphatics (Transport and Circulation); Cell Biology; Clinical Chemistry (Allied Medical Sciences); Gastroenterology (Human Medicine, Medical Sciences); Genetics; Oncology (Human Medicine, Medical Sciences)
IT Miscellaneous Descriptors
ADENOCARCINOMA; ADJACENT NON-TUMOR TISSUE; CARCINOGENESIS; ESOPHAGEAL **CANCER**; FRAMESHIFT MUTATION; GENE DELETION; GENE REARRANGEMENT; INSERTION MUTATION; POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA; TRANSITION MUTATION; TUMOR SUPPRESSOR GENE
ORGN Super Taxa
Hominidae: Primates, Mammalia, Vertebrata, Chordata, Animalia
ORGN Organism Name
Hominidae (Hominidae)
ORGN Organism Superterms
animals; chordates; humans; mammals; primates; vertebrates

L4 ANSWER 1 OF 7 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 1994:532148 BIOSIS
DN PREV199497545148
TI Mutation of p53 gene in human **cancers** of the esophagus and gastric cardia.
AU Li, Huan-Chuan; Lu, Shi-Xin
CS Cancer Inst., Chinese Academy Med. Sci. Peking Union Med. College, Beijing 100021 China
SO Zhonghua Zhongliu Zazhi (1994) Vol. 16, No. 3, pp. 172-176.
ISSN: 0253-3758.
DT Article
LA Chinese
SL Chinese; English
AB p53 gene in human esophageal **cancer** (EC) and **cancer** of gastric cardia was analyzed. Southern blotting hybridization revealed that five of 35 of EC sample were found to contain abnormal structure of **p63** gene, including 2 deletions and 3 rearrangements; two of 27 adjacent non-tumor tissues also contain abnormal structure of p53 gene (7.4%), among them one case was fragment deletion and another case was rearrangement. PCR-direct sequencing technique was used to detect p53 point mutation within exon and intron 5 through 9. Fifteen of 30(50%) of esophageal squamous cell carcinomas contained mutation of p53 gene. Five of 11(45%) adjacent non-tumor tissues also contained mutation of p53 gene. An esophageal adenocarcinoma shoved p53 mutation. Three of 4 carcinoma of gastric cardia showed p53 mutation. Mutation spectrum in EC: 8 OF 22 cases (36.4%) of p53 mutation were G:C to A:T transition, 6 of 22 cases (27.3%) of p53 mutation were frameshift mutation, including 13.6% (3/22) insertion and 9.1% (2/22) deletion mutation. Some new sites of p53 mutation in human EC were identified. The results suggest that the p53 gene plays an important role in carcinogenesis of human esophagus and gastric cardia.
CC Cytology and Cytochemistry - Human *02508
Genetics and Cytogenetics - Human *03508
Clinical Biochemistry; General Methods and Applications *10006
Biochemical Studies - Nucleic Acids, Purines and Pyrimidines 10062
Biochemical Studies - Proteins, Peptides and Amino Acids 10064
Digestive System - Pathology *14006
Blood, Blood-Forming Organs and Body Fluids - Blood Cell Studies *15004
Neoplasms and Neoplastic Agents - Biochemistry *24006
Neoplasms and Neoplastic Agents - Carcinogens and Carcinogenesis *24007
BC Hominidae *86215
IT Major Concepts
Blood and Lymphatics (Transport and Circulation); Cell Biology; Clinical Chemistry (Allied Medical Sciences); Gastroenterology (Human Medicine, Medical Sciences); Genetics; Oncology (Human Medicine, Medical Sciences)
IT Miscellaneous Descriptors
ADENOCARCINOMA; ADJACENT NON-TUMOR TISSUE; CARCINOGENESIS; ESOPHAGEAL **CANCER**; FRAMESHIFT MUTATION; GENE DELETION; GENE REARRANGEMENT; INSERTION MUTATION; POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA; TRANSITION MUTATION; TUMOR SUPPRESSOR GENE
ORGN Super Taxa
Hominidae: Primates, Mammalia, Vertebrata, Chordata, Animalia
ORGN Organism Name
Hominidae (Hominidae)
ORGN Organism Superterms
animals; chordates; humans; mammals; primates; vertebrates

L7 ANSWER 1 OF 39 MEDLINE
AN 2002038003 MEDLINE
DN 21606643 PubMed ID: 11764070
TI Value of **p63** and cytokeratin 5/6 as immunohistochemical markers for the differential **diagnosis** of poorly differentiated and undifferentiated **carcinomas**.
AU Kaufmann O; Fietze E; Mengs J; Dietel M
CS Institute of Pathology, Charite University Hospital, Berlin, Germany.
SO AMERICAN JOURNAL OF CLINICAL PATHOLOGY, (2001 Dec) 116 (6) 823-30.
Journal code: 0370470. ISSN: 0002-9173.
CY United States
DT (EVALUATION STUDIES)
Journal; Article; (JOURNAL ARTICLE)
LA English
FS Abridged Index Medicus Journals; Priority Journals
EM 200201
ED Entered STN: 20020124
Last Updated on STN: 20020125
Entered Medline: 20020103

L7 ANSWER 2 OF 39 MEDLINE
AN 2001553651 MEDLINE
DN 21486168 PubMed ID: 11600462
TI Expression of the p53 homologue p63alpha and DeltaNp63alpha in the neoplastic sequence of Barrett's oesophagus: correlation with morphology and p53 protein.
AU Hall P A; Woodman A C; Campbell S J; Shepherd N A
CS Department of Histopathology, Gloucestershire Royal Hospital, Great Western Road, Gloucester GL1 3NN, UK.
SO GUT, (2001 Nov) 49 (5) 618-23.
Journal code: 2985108R. ISSN: 0017-5749.
CY England: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Abridged Index Medicus Journals; Priority Journals
EM 200112
ED Entered STN: 20011016
Last Updated on STN: 20020122
Entered Medline: 20011205

L7 ANSWER 3 OF 39 MEDLINE
AN 2001427028 MEDLINE
DN 21367355 PubMed ID: 11474290
TI **p63**, a p53 homologue, is a selective nuclear marker of myoepithelial cells of the human breast.
AU Barbareschi M; Pecciarini L; Cangi M G; Macri E; Rizzo A; Viale G; Doglioni C
CS Department of Pathology, San Martino Hospital, Trento, Italy.
SO AMERICAN JOURNAL OF SURGICAL PATHOLOGY, (2001 Aug) 25 (8) 1054-60.
Journal code: 3YV; 7707904. ISSN: 0147-5185.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200108
ED Entered STN: 20010820
Last Updated on STN: 20010820
Entered Medline: 20010816

L7 ANSWER 4 OF 39 MEDLINE
AN 2001346075 MEDLINE
DN 21275530 PubMed ID: 11381365
TI Histologic and immunophenotypic classification of cervical **carcinomas** by expression of the p53 homologue **p63**: a study of 250 cases.
AU Wang T Y; Chen B F; Yang Y C; Chen H; Wang Y; Cviko A; Quade B J; Sun D; Yang A; McKeon F D; Crum C P
CS Department of Pathology and Obstetrics and Gynecology, MacKay Memorial Hospital, Taipei, Taiwan.
NC CA72594 (NCI)
CA75340 (NCI)
SO HUMAN PATHOLOGY, (2001 May) 32 (5) 479-86.
Journal code: GEC; 9421547. ISSN: 0046-8177.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200107
ED Entered STN: 20010709
Last Updated on STN: 20010709
Entered Medline: 20010705

L7 ANSWER 5 OF 39 MEDLINE
AN 2001254912 MEDLINE
DN 21251212 PubMed ID: 11353064
TI Pulmonary epithelial-myoepithelial tumor of unproven **malignant** potential: report of a case and review of the literature.
AU Pelosi G; Fraggetta F; Maffini F; Solli P; Cavallon A; Viale G
CS Department of Pathology and Laboratory Medicine, European Institute of Oncology and University of Milan School of Medicine, Italy.. giuseppe.pelosi@ieo.it
SO MODERN PATHOLOGY, (2001 May) 14 (5) 521-6. Ref: 23
Journal code: PTH; 8806605. ISSN: 0893-3952.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW OF REPORTED CASES)
LA English
FS Priority Journals
EM 200107
ED Entered STN: 20010709
Last Updated on STN: 20010709
Entered Medline: 20010705

L7 ANSWER 6 OF 39 MEDLINE
AN 2000463853 MEDLINE
DN 20468898 PubMed ID: 11016683
TI The p53 molecule and its prognostic role in squamous cell **carcinomas** of the head and neck.
AU Nylander K; Dabelsteen E; Hall P A
CS Department of Medical Biosciences/Pathology, Umea University, Sweden.
SO JOURNAL OF ORAL PATHOLOGY AND MEDICINE, (2000 Oct) 29 (9) 413-25. Ref: 91
Journal code: JRF. ISSN: 0904-2512.
CY Denmark
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)
LA English
FS Dental Journals; Priority Journals
EM 200101
ED Entered STN: 20010322
Last Updated on STN: 20010322
Entered Medline: 20010111

L7 ANSWER 7 OF 39 MEDLINE
AN 2000406720 MEDLINE
DN 20374132 PubMed ID: 10918601
TI High level expression of deltaN-**p63**: a mechanism for the

inactivation of p53 in undifferentiated nasopharyngeal **carcinoma** (NPC)?.
AU Crook T; Nicholls J M; Brooks L; O'Nions J; Allday M J
CS Ludwig Institute for Cancer Research and Section of Virology and Cell Biology, Imperial College of Science, Technology and Medicine, London, UK.
SO ONCOGENE, (2000 Jul 13) 19 (30) 3439-44.
Journal code: ONC; 8711562. ISSN: 0950-9232.
CY ENGLAND: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200008
ED Entered STN: 20000901
Last Updated on STN: 20000901
Entered Medline: 20000818

L7 ANSWER 8 OF 39 MEDLINE
AN 2000062989 MEDLINE
DN 20062989 PubMed ID: 10594758
TI Association of **p63** with proliferative potential in normal and neoplastic human keratinocytes.
AU Parsa R; Yang A; McKeon F; Green H
CS Department of Cell Biology, Harvard Medical School, Boston, Massachusetts 02115, USA.
SO JOURNAL OF INVESTIGATIVE DERMATOLOGY, (1999 Dec) 113 (6) 1099-105.
Journal code: IHZ; 0426720. ISSN: 0022-202X.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200001
ED Entered STN: 20000124
Last Updated on STN: 20000124
Entered Medline: 20000113

L7 ANSWER 9 OF 39 CANCERLIT
AN 2000468898 CANCERLIT
DN 20468898
TI The p53 molecule and its prognostic role in squamous cell **carcinomas** of the head and neck.
AU Nylander K; Dabelsteen E; Hall P A
CS Department of Medical Biosciences/Pathology, Umea University, Sweden.
SO JOURNAL OF ORAL PATHOLOGY AND MEDICINE, (2000). Vol. 29, No. 9, pp. 413-25.
Journal code: JRF. ISSN: 0904-2512.
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)
FS MEDL; L; Dental Journals; I
LA English
OS MEDLINE 20468898
EM 200102

L7 ANSWER 10 OF 39 CANCERLIT
AN 2000374132 CANCERLIT
DN 20374132
TI High level expression of deltaN-**p63**: a mechanism for the inactivation of p53 in undifferentiated nasopharyngeal **carcinoma** (NPC)?.
AU Crook T; Nicholls J M; Brooks L; O'Nions J; Allday M J
CS Ludwig Institute for Cancer Research and Section of Virology and Cell Biology, Imperial College of Science, Technology and Medicine, London, UK.
SO ONCOGENE, (2000). Vol. 19, No. 30, pp. 3439-44.
Journal code: ONC. ISSN: 0950-9232.
DT Journal; Article; (JOURNAL ARTICLE)
FS MEDL; L; Priority Journals; Cancer Journals
LA English
OS MEDLINE 20374132
EM 200009

L7 ANSWER 11 OF 39 CANCERLIT
AN 2000062989 CANCERLIT
DN 20062989
TI Association of **p63** with proliferative potential in normal and neoplastic human keratinocytes.
AU Parsa R; Yang A; McKeon F; Green H
CS Department of Cell Biology, Harvard Medical School, Boston, Massachusetts 02115, USA.
SO JOURNAL OF INVESTIGATIVE DERMATOLOGY, (1999). Vol. 113, No. 6, pp. 1099-105.
Journal code: IHZ. ISSN: 0022-202X.
DT Journal; Article; (JOURNAL ARTICLE)
FS MEDL; L; Priority Journals; Cancer Journals
LA English
OS MEDLINE 20062989
EM 200002

L7 ANSWER 12 OF 39 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
AN 2002033960 EMBASE
TI Plasmablastic lymphoma: An HIV-associated entity with primary oral manifestations.
AU Flaitz C.M.; Nichols C.M.; Walling D.M.; Hicks M.J.
CS C.M. Flaitz, Department of Stomatology, Univ. Texas-Houston Hlth. Sci. Ctr., Dental Branch, 6516 John Freeman Avenue, Houston, TX 77030, United States. cmflaitz@mail.uth.db.edu
SO Oral Oncology, (2002) 38/1 (96-102).
Refs: 30
ISSN: 1368-8375 CODEN: EJCCER
PUI S 1368-8375(01)00018-5
CY United Kingdom
DT Journal; Article
FS 004 Microbiology
011 Otorhinolaryngology
016 Cancer
026 Immunology, Serology and Transplantation
037 Drug Literature Index
LA English
SL English

L7 ANSWER 13 OF 39 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
AN 2001422538 EMBASE
TI Value of **p63** and cytokeratin 5/6 as immunohistochemical markers for the differential **diagnosis** of poorly differentiated and undifferentiated **carcinomas**.
AU Kaufmann O.; Fietze E.; Mengs J.; Dietel M.
CS Dr. E. Fietze, Institute of Pathology, Charite University Hospital, Schumannstr. 20/21, 10117 Berlin, Germany
SO American Journal of Clinical Pathology, (2001) 116/6 (823-830).
Refs: 31
ISSN: 0002-9173 CODEN: AJCPAI
CY United States
DT Journal; Article
FS 005 General Pathology and Pathological Anatomy
016 Cancer
026 Immunology, Serology and Transplantation
LA English
SL English

L7 ANSWER 14 OF 39 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
AN 2001374840 EMBASE
TI Expression of the p53 homologue **p63**.alpha. and .delta.Np63.alpha. in the neoplastic sequence of Barrett's oesophagus: Correlation with morphology and p53 protein.
AU Hall P.A.; Woodman A.C.; Campbell S.J.; Shepherd N.A.
CS Prof. N.A. Shepherd, Department of Histopathology, Gloucestershire Royal Hospital, Great Western Road, Gloucester GL1 3NN, United Kingdom. neil.shepherd@gloucr-tr.swest.nhs.uk
SO Gut, (2001) 49/5 (618-623).
Refs: 44
ISSN: 0017-5749 CODEN: GUTTAK
CY United Kingdom
DT Journal; Article
FS 005 General Pathology and Pathological Anatomy
048 Gastroenterology
LA English
SL English

L7 ANSWER 15 OF 39 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
AN 2001338244 EMBASE
TI Expression of the p53 homologues **p63** and p73 in multiple simultaneous gastric **cancer**.
AU Tannapfel A.; Schmelzer S.; Benicke M.; Klimpfinger M.; Kohlhaw K.; Mossner J.; Engeland K.; Wittekind C.
CS A. Tannapfel, institute of Pathology, University of Leipzig, Liebigstrasse 26, 04103 Leipzig, Germany. tana@medizin.uni-leipzig.de
SO Journal of Pathology, (2001) 195/2 (163-170).
Refs: 30
ISSN: 0022-3417 CODEN: JPTLAS
CY United Kingdom
DT Journal; Article
FS 005 General Pathology and Pathological Anatomy
016 Cancer
029 Clinical Biochemistry
048 Gastroenterology
LA English
SL English

L7 ANSWER 16 OF 39 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
AN 2001264790 EMBASE
TI **p63**, a p53 homologue, is a selective nuclear marker of myoepithelial cells of the human breast.
AU Barbareschi M.; Pecciarini L.; Cangi M.G.; Macri E.; Rizzo A.; Viale G.; Doglioni C.
CS Dr. C. Doglioni, Anatonomia Patologica Ospedale, 32100 Belluno, Italy. claudio.doglioni@ulss.belluno.it
SO American Journal of Surgical Pathology, (2001) 25/8 (1054-1060).
Refs: 34
ISSN: 0147-5185 CODEN: AJSPDX
CY United States
DT Journal; Article
FS 005 General Pathology and Pathological Anatomy
016 Cancer
LA English
SL English

L7 ANSWER 17 OF 39 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
AN 2001199282 EMBASE
TI Histologic and immunophenotypic classification of cervical **carcinomas** by expression of the p53 homologue **p63**: A study of 250 cases.
AU Wang T.-Y.; Chen B.-F.; Yang Y.-C.; Chen H.; Wang Y.; Cviko A.; Quade B.J.; Sun D.; Yang A.; McKeon F.D.; Crum C.P.
CS Dr. C.P. Crum, Department of Pathology, Brigham and Women's Hospital, 75 Francis St., Boston, MA 02115, United States
SO Human Pathology, (2001) 32/5 (479-486).
Refs: 33
ISSN: 0046-8177 CODEN: HPCQA4
CY United States
DT Journal; Article
FS 005 General Pathology and Pathological Anatomy
LA English
SL English

L7 ANSWER 18 OF 39 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
AN 2000438051 EMBASE
TI **p63** is a prostate basal cell marker and is required for prostate development.
AU Signoretti S.; Waltregny D.; Dilks J.; Isaac B.; Lin D.; Garraway L.; Yang A.; Montironi R.; McKeon F.; Loda M.
CS M. Loda, Department of Adult Oncology, Dana Farber Cancer Institute, Dana 740B, 44 Binney St., Boston, MA 02215, United States
SO American Journal of Pathology, (2000) 157/6 (1769-1775).
Refs: 27
ISSN: 0002-9440 CODEN: AJPAA4
CY United States
DT Journal; Article
FS 005 General Pathology and Pathological Anatomy
016 Cancer
028 Urology and Nephrology
029 Clinical Biochemistry
LA English
SL English

L7 ANSWER 19 OF 39 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
AN 2000360999 EMBASE
TI Stratified mucin-producing intraepithelial lesions of the cervix: Adenosquamous or columnar cell neoplasia?.
AU Park J.-J.; Sun D.; Quade B.J.; Flynn C.; Sheets E.E.; Yang A.; McKeon F.; Crum C.P.
CS Dr. C.P. Crum, Department of Pathology, Brigham and Women's Hospital, 75 Francis St., Boston, MA 02115, United States. ccrum@partners.org
SO American Journal of Surgical Pathology, (2000) 24/10 (1414-1419).
Refs: 20
ISSN: 0147-5185 CODEN: AJSPDX
CY United States
DT Journal; Article
FS 005 General Pathology and Pathological Anatomy
010 Obstetrics and Gynecology
016 Cancer
LA English
SL English

L7 ANSWER 20 OF 39 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
AN 2000260441 EMBASE
TI High level expression of .DELTA.N-**p63**: A mechanism for the inactivation of p53 in undifferentiated nasopharyngeal **carcinoma** (NPC)?.
AU Crook T.; Nicholls J.M.; Brooks L.; O'Nions J.; Allday M.J.
CS M.J. Allday, Ludwig Institute for Cancer Research, Imperial College Sci. Technol. Med., St. Mary's Campus, Norfolk Place, London W2 1PG, United Kingdom
SO Oncogene, (13 Jul 2000) 19/30 (3439-3444).
Refs: 42
ISSN: 0950-9232 CODEN: ONCNES
CY United Kingdom
DT Journal; (Short Survey)

FS 011 Otorhinolaryngology
016 Cancer
022 Human Genetics
LA English
SL English

L7 ANSWER 21 OF 39 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
AN 2000244220 EMBASE
TI Adenoid basal **carcinomas** of the cervix: A unique morphological evolution with cell cycle correlates.
AU Cviko A.; Briem B.; Granter S.R.; Hinto A.P.; Wang T.-Y.; Yang Y.-C.; Chen B.-F.; Yang A.; Sheets E.E.; McKeon F.D.; Crum C.P.
CS Dr. C.P. Crum, Department of Pathology, Brigham and Women's Hospital, 75 Francis St., Boston, MA 02115, United States
SO Human Pathology, (2000) 31/6 (740-744).
Refs: 19
ISSN: 0046-8177 CODEN: HPCQA4
CY United States
DT Journal; Article
FS 005 General Pathology and Pathological Anatomy
010 Obstetrics and Gynecology
016 Cancer
LA English
SL English

L7 ANSWER 22 OF 39 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 2002:74400 BIOSIS
DN PREV200200074400
TI Value of **p63** and cytokeratin 5/6 as immunohistochemical markers for the differential **diagnosis** of poorly differentiated and undifferentiated **carcinomas**.
AU Kaufmann, Olaf; Fietze, Ellen (1); Mengs, Joerg; Dietel, Manfred
CS (1) Institute of Pathology, Charite University Hospital, Schumannstr. 20/21, 10117, Berlin Germany
SO American Journal of Clinical Pathology, (December, 2001) Vol. 116, No. 6, pp. 823-830. http://www.ajcp.com. print.
ISSN: 0002-9173.
DT Article
LA English

L7 ANSWER 23 OF 39 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 2001:544459 BIOSIS
DN PREV200100544459
TI Expression of the p53 homologue p63alpha and DELTANp63alpha in the neoplastic sequence of Barrett's oesophagus: Correlation with morphology and p53 protein.
AU Hall, P. A.; Woodman, A. C.; Campbell, S. J.; Shepherd, N. A. (1)
CS (1) Department of Histopathology, Gloucestershire Royal Hospital, Great Western Road, Gloucester, GL1 3NN: neil.shepherd@gloucr-tr.swest.nhs.uk UK
SO Gut, (November, 2001) Vol. 49, No. 5, pp. 618-623. print.
ISSN: 0017-5749.
DT Article
LA English
SL English

L7 ANSWER 24 OF 39 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 2001:407666 BIOSIS
DN PREV200100407666
TI **p63**, a p53 homologue, is a selective nuclear marker of myoepithehal cells of the human breast.
AU Barbareschi, Mattia; Pecciarini, Lorenza; Cangi, M. Giulia; Macri, Ettore; Rizzo, Aroldo; Viale, Giuseppe; Doglioni, Claudio (1)
CS (1) Anatomia Patologica Ospedale, 32100, Belluno: claudio.doglioni@ulss.belluno.it Italy
SO American Journal of Surgical Pathology, (August, 2001) Vol. 25, No. 8, pp. 1054-1060. print.
ISSN: 0147-5185.
DT Article
LA English
SL English

L7 ANSWER 25 OF 39 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 2001:376511 BIOSIS
DN PREV200100376511
TI Histologic and immunophenotypic classification of cervical **carcinomas** by expression of the p53 homologue **p63**: A study of 250 cases.
AU Wang, Tao-Yeuan; Chen, Be-Fong; Yang, Yuh-Cheng; Chen, Hao; Wang, Yunmei; Cviko, Aida; Quade, Bradley J.; Sun, Deqin; Yang, Annie; McKeon, Frank D.; Crum, Christopher P. (1)
CS (1) Department of Pathology, Brigham and Women's Hospital, 75 Francis St, Boston, MA, 02115 USA
SO Human Pathology, (May, 2001) Vol. 32, No. 5, pp. 479-486. print.
ISSN: 0046-8177.
DT Article
LA English
SL English

L7 ANSWER 26 OF 39 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 2001:133636 BIOSIS
DN PREV200100133636
TI Immunohistochemical study of expression of p53-homolog **p63**, in pulmonary **neoplasms**.
AU Kaufman, D. (1); Wang, B. Y. (1); Gil, J. (1); Gan, L. (1); Kohtz, D. S.; Burstein, D. E.
CS (1) Department of Pathology, Mount Sinai School of Medicine, New York, NY USA
SO Laboratory Investigation, (January, 2001) Vol. 81, No. 1, pp. 221A. print.
Meeting Info.: Annual Meeting of the United States and Canadian Academy of Pathology Atlanta, Georgia, USA March 03-09, 2001
ISSN: 0023-6837.
DT Conference
LA English
SL English

L7 ANSWER 27 OF 39 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 2001:118902 BIOSIS
DN PREV200100118902
TI Expression of **p63** protein in subtypes of transitional cell and renal cell **carcinomas**.
AU Black, C. C. (1); Unger, P. D. (1); Gans, W. H.; Droller, M. J.; Kohtz, D. S. (1); Gan, L. (1); Burstein, D. E. (1)
CS (1) Department of Pathology and Ruttenberg Cancer Center, Mount Sinai School of Medicine, New York, NY USA
SO Laboratory Investigation, (January, 2001) Vol. 81, No. 1, pp. 102A. print.
Meeting Info.: Annual Meeting of the United States and Canadian Academy of Pathology Atlanta, Georgia, USA March 03-09, 2001
ISSN: 0023-6837.
DT Conference
LA English
SL English

L7 ANSWER 28 OF 39 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 2001:117450 BIOSIS
DN PREV200100117450
TI Expression of **p63** in papillary thyroid **carcinoma** and in Hashimoto's thyroiditis: A common link.
AU Ewart, Michelle (1); Unger, Pamela (1); Gan, Li (1); Kohtz, D. Stave;

Burstein, David E.
CS (1) Department of Pathology, Mount Sinai School of Medicine, New York, NY USA
SO Laboratory Investigation, (January, 2001) Vol. 81, No. 1, pp. 75A. print.
Meeting Info.: Annual Meeting of the United States and Canadian Academy of Pathology Atlanta, Georgia, USA March 03-09, 2001
ISSN: 0023-6837.
DT Conference
LA English
SL English

L7 ANSWER 29 OF 39 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 2000:471721 BIOSIS
DN PREV200000471721
TI Stratified mucin-producing intraepithelial lesions of the cervix: Adenosquamous or columnar cell neoplasia.
AU Park, Jeong-Ja; Sun, Deqin; Quade, Bradley J.; Flynn, Cythia; Sheets, Ellen E.; Yang, Annie; McKeon, Frank; Crum, Christopher P. (1)
CS (1) Department of Pathology, Brigham and Women's Hospital, 75 Francis St., Boston, MA, 02115 USA
SO American Journal of Surgical Pathology, (October, 2000) Vol. 24, No. 10, pp. 1414-1419. print.
ISSN: 0147-5185.
DT Article
LA English
SL English

L7 ANSWER 30 OF 39 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 2000:374796 BIOSIS
DN PREV200000374796
TI High level expression of DELTAN-**p63**: A mechanism for the inactivation of p53 in undifferentiated nasopharyngeal **carcinoma** (NPC.
AU Crook, Tim; Nicholls, John M.; Brooks, Louise; O'Nions, Jenny; Allday, Martin J. (1)
CS (1) Section of Virology and Cell Biology, Imperial College of Science, Technology and Medicine, Ludwig Institute for Cancer Research, Norfolk Place, St Mary's Campus, London, W2 1PG UK
SO Oncogene, (13 July, 2000) Vol. 19, No. 30, pp. 3439-3444. print.
ISSN: 0950-9232.
DT Article
LA English
SL English

L7 ANSWER 31 OF 39 CAPLUS COPYRIGHT 2002 ACS
AN 2001:888455 CAPLUS
DN 136:148755
TI Classification of human lung **carcinomas** by mRNA expression profiling reveals distinct adenocarcinoma subclasses
AU Bhattacharjee, Arindam; Richards, William G.; Staunton, Jane; Li, Cheng; Monti, Stefano; Vasa, Priya; Ladd, Christine; Beheshti, Javad; Bueno, Raphael; Gillette, Michael; Loda, Massimo; Weber, Griffin; Mark, Eugene J.; Lander, Eric S.; Wong, Wing; Johnson, Bruce E.; Golub, Todd R.; Sugarbaker, David J.; Meyerson, Matthew
CS Department of Adult Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, 02115, USA
SO Proceedings of the National Academy of Sciences of the United States of America (2001), 98(24), 13790-13795
CODEN: PNASA6; ISSN: 0027-8424
PB National Academy of Sciences
DT Journal
LA English
RE.CNT 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 32 OF 39 CAPLUS COPYRIGHT 2002 ACS
AN 2000:557977 CAPLUS
DN 133:250512
TI High level expression of .DELTA.N-**p63**: a mechanism for the inactivation of p53 in undifferentiated nasopharyngeal **carcinoma** (NPC)?
AU Crook, Tim; Nicholls, John M.; Brooks, Louise; O'Nions, Jenny; Allday, Martin J.
CS Ludwig Institute for Cancer Research and Section of Virology and Cell Biology, Imperial College of Science, Technology and Medicine, London, W2 1PG, UK
SO Oncogene (2000), 19(30), 3439-3444
CODEN: ONCNES; ISSN: 0950-9232
PB Nature Publishing Group
DT Journal
LA English
RE.CNT 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 33 OF 39 CAPLUS COPYRIGHT 2002 ACS
AN 1999:640874 CAPLUS
DN 131:270497
TI A new short member of the p53 family (p40) acts as an oncogene
IN Trink, Barry; Jen, Jin; Ratovitski, Edward; Sidransky, David
PA The Johns Hopkins University, USA
SO PCT Int. Appl., 63 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9950287	A2	19991007	WO 1999-US6657	19990326
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9932086	A1	19991018	AU 1999-32086	19990326
PRAI US 1998-79736P	A2	19980327		
WO 1999-US6657	W	19990326		

L7 ANSWER 34 OF 39 USPATFULL
AN 2002:78410 USPATFULL
TI p53 binding areas
IN Krammer, Peter, Heidelberg, GERMANY, FEDERAL REPUBLIC OF
Muller-Schilling, Martina, Heidelberg, GERMANY, FEDERAL REPUBLIC OF
Oren, Moshe, Rehovot, ISRAEL
PA Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts (non-U.S. corporation)
PI US 2002042064 A1 20020411
AI US 2001-834291 A1 20010412 (9)
PRAI WO 1999-DE3343 19991018
DE 1998-DE19847779 19981015
DT Utility
FS APPLICATION
LN.CNT 601
INCL INCLM: 435/006.000
INCLS: 435/320.100; 435/007.230; 536/023.500

NCL NCLM: 435/006.000
NCLS: 435/320.100; 435/007.230; 536/023.500
IC [7]
ICM: C12Q001-68
ICS: G01N033-574; C07H021-04

L7 ANSWER 35 OF 39 USPATFULL
AN 2002:72855 USPATFULL
TI Treatment of hearing impairments
IN Gao, Wei-Qiang, Foster City, CA, UNITED STATES
PI US 2002039995 A1 20020404
AI US 2001-823717 A1 20010330 (9)
RLI Continuation of Ser. No. US 1997-778357, filed on 2 Jan 1997, GRANTED, Pat. No. US 6225282
PRAI US 1996-44407P 19960105 (60)
DT Utility
FS APPLICATION
LN.CNT 3389
INCL INCLM: 514/002.000
INCLS: 424/130.100
NCL NCLM: 514/002.000
NCLS: 424/130.100
IC [7]
ICM: A61K039-395
ICS: A61K038-17

L7 ANSWER 36 OF 39 USPATFULL
AN 2001:63659 USPATFULL
TI Treatment of hearing impairments
IN Gao, Wei-Qiang, Foster City, CA, United States
PA Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)
PI US 6225282 B1 20010501
AI US 1997-778357 19970102 (8)
PRAI US 1996-44407P 19960105 (60)
DT Utility
FS Granted
LN.CNT 3619
INCL INCLM: 514/002.000
INCLS: 514/012.000; 514/192.000; 514/198.000; 514/199.000
NCL NCLM: 514/002.000
NCLS: 514/012.000; 514/192.000; 514/198.000; 514/199.000
IC [7]
ICM: A61K038-00
ICS: A61K031-43
EXF 514/192; 514/198; 514/199; 514/2; 514/12
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 37 OF 39 USPATFULL
AN 2000:64711 USPATFULL
TI Growth factor inducible serine/threonine phosphatase fin13
IN Guthridge, Mark A., South Australia, Australia
Basilico, Claudio, New York, NY, United States
Bellosta, Paola, New York, NY, United States
PA New York University, New York, NY, United States (U.S. corporation)
PI US 6066485 20000523
AI US 1997-935855 19970923 (8)
RLI Continuation-in-part of Ser. No. US 1997-822701, filed on 21 Mar 1997, now patented, Pat. No. US 5976853
PRAI US 1996-13792P 19960321 (60)
DT Utility
FS Granted
LN.CNT 4106
INCL INCLM: 435/196.000
INCLS: 435/195.000; 530/350.000; 530/300.000; 536/023.200
NCL NCLM: 435/196.000
NCLS: 435/195.000; 530/300.000; 530/350.000; 536/023.200
IC [7]
ICM: C12N009-16
EXF 435/496; 435/195; 435/252.3; 435/252.33; 435/325; 435/320.1; 536/23.2
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 38 OF 39 USPATFULL
AN 1999:137002 USPATFULL
TI Growth factor inducible serine/threonine phosphatase FIN13
IN Guthridge, Mark A., New York, NY, United States
Basilico, Claudio, New York, NY, United States
PA New York University Medical Center, New York, NY, United States (U.S. corporation)
PI US 5976853 19991102
AI US 1997-822701 19970321 (8)
PRAI US 1996-13792P 19960321 (60)
DT Utility
FS Granted
LN.CNT 3782
INCL INCLM: 435/196.000
INCLS: 435/195.000; 435/325.000; 435/252.300; 435/252.330; 435/235.100; 435/320.100; 536/023.100; 536/023.200; 536/023.500
NCL NCLM: 435/196.000
NCLS: 435/195.000; 435/235.100; 435/252.300; 435/252.330; 435/320.100; 435/325.000; 536/023.100; 536/023.200; 536/023.500
IC [6]
ICM: C12N009-16
ICS: C07H021-04
EXF 435/196; 435/252.3; 435/252.33; 435/325; 435/320.1; 435/195; 435/235.1; 536/23.1; 536/23.2; 536/23.5
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 39 OF 39 USPATFULL
AN 96:5704 USPATFULL
TI Nucleotide sequences useful as type specific probes, PCR primers and LCR probes for the amplification and detection of human papilloma virus, and related kits and methods
IN Bouma, Stanley R., Mundelein, IL, United States
Joseph, Jeffrey L., Cherry Hill, NJ, United States
Marshall, Ronald L., Zion, IL, United States
Laffler, Thomas G., Libertyville, IL, United States
PA Abbott Laboratories, Abbott Park, IL, United States (U.S. corporation)
PI US 5484699 19960116
AI US 1994-316293 19940930 (8)
RLI Continuation of Ser. No. US 1992-965665, filed on 22 Oct 1992, now abandoned which is a continuation-in-part of Ser. No. US 1990-589948, filed on 28 Sep 1990, now abandoned And a continuation-in-part of Ser. No. US 1990-590105, filed on 28 Sep 1990, now abandoned And a continuation-in-part of Ser. No. US 1990-590253, filed on 28 Sep 1990, now abandoned
DT Utility
FS Granted
LN.CNT 1679
INCL INCLM: 435/005.000
INCLS: 536/023.100; 536/023.720
NCL NCLM: 435/005.000
NCLS: 536/023.100; 536/023.720
IC [6]
ICM: C12Q001-70
ICS: C07H021-02; C07H021-04
EXF 435/5; 435/6; 935/77; 935/78; 536/23.1; 536/23.72; 536/24.3
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

```
=> d his

     (FILE 'HOME' ENTERED AT 10:35:21 ON 11 APR 2002)

     FILE 'MEDLINE, CANCERLIT, EMBASE, BIOSIS, CAPLUS, USPATFULL' ENTERED AT
     10:36:25 ON 11 APR 2002
L1          4008 S P63 OR P63 GENE
L2       3824815 S CANCER? OR MALIGNANT? OR NEOPLASM?
L3           325 S L1 AND L2
L4       1304621 S CARCINOMA?
L5           128 S L4 AND L3
L6       4957279 S DIAGNOS?
L7            39 S L5 AND L6
L8       2114047 S ANTIBOD?
L9           273 S L1 AND L8
L10          160 S L9 NOT PY=>1999
L11            4 S L10 AND L4

=> s l4 and l1
L12         171 L4 AND L1

=> s l12 not py=>1999
L13          11 L12 NOT PY=>1999

=> d l13 1-11

L13  ANSWER 1 OF 11  BIOSIS  COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN   1994:532148  BIOSIS
DN   PREV199497545148
TI   Mutation of p53 gene in human cancers of the esophagus and gastric cardia.
AU   Li, Huan-Chuan; Lu, Shi-Xin
CS   Cancer Inst., Chinese Academy Med. Sci. Peking Union Med. College, Beijing
     100021 China
SO   Zhonghua Zhongliu Zazhi, (1994) Vol. 16, No. 3, pp. 172-176.
     ISSN: 0253-3758.
DT   Article
LA   Chinese
SL   Chinese; English

L13  ANSWER 2 OF 11  BIOSIS  COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN   1994:451861  BIOSIS
DN   PREV199497464861
TI   P53 Protein accumulation in lung carcinomas of patients exposed
     to asbestos and tobacco smoke.
AU   Nuorva, Kyosti; Makitaro, Riitta; Huhti, Esko; Kamel, Dia; Vahakangas,
     Kirsi; Bloigu, Risto; Soini, Ylermi; Paakko, Paavo (1)
CS   (1) Dep. Pathol., Univ. Oulu, Kajaanintie 52D, 90220 Oulu Finland
SO   American Journal of Respiratory and Critical Care Medicine, (1994) Vol.
     150, No. 2, pp. 528-533.
DT   Article
LA   English

L13  ANSWER 3 OF 11  BIOSIS  COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN   1983:191835  BIOSIS
DN   BA75:41835
TI   ANTIBODIES AGAINST A SYNTHETIC PEPTIDE OF THE POLIOVIRUS REPLICASE PROTEIN
     REACTION WITH NATIVE VIRUS ENCODED PROTEINS AND INHIBITION OF VIRUS
     SPECIFIC POLYMERASE ACTIVITIES IN-VITRO.
AU   BARON M H; BALTIMORE D
CS   CENTER FOR CANCER RESEARCH AND DEPARTMENT OF BIOLOGY, MASSACHUSETTS
     INSTITUTE OF TECHNOLOGY, CAMBRIDGE, MASSACHUSETTS 02139.
SO   J VIROL, (1982) 43 (3), 969-978.
     CODEN: JOVIAM. ISSN: 0022-538X.
FS   BA; OLD
LA   English

L13  ANSWER 4 OF 11  BIOSIS  COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN   1983:152879  BIOSIS
DN   BA75:2879
TI   A GENE PRODUCT OF THE MOUSE T COMPLEX WITH CHEMICAL PROPERTIES OF A CELL
     SURFACE ASSOCIATED COMPONENT OF THE EXTRACELLULAR MATRIX.
AU   SILVER L M; WHITE M
CS   COLD SPRING HARBOR LAB., COLD SPRING HARBOR, NEW YORK 11724.
SO   DEV BIOL, (1982) 91 (2), 423-430.
     CODEN: DEBIAO. ISSN: 0012-1606.
FS   BA; OLD
LA   English

L13  ANSWER 5 OF 11  BIOSIS  COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN   1982:295665  BIOSIS
DN   BA74:68145
TI   GENOME LENGTH COPIES OF POLIOVIRION RNA ARE SYNTHESIZED IN-VITRO BY THE
     POLIOVIRUS RNA DEPENDENT RNA POLYMERASE.
AU   VAN KYKE T A; RICKLES R J; FLANEGAN J B
CS   DEP. IMMUNOL. MED. MICROBIOL., COLL. MED., UNIV. FLORIDA, GAINESVILLE,
     FLA. 32610.
SO   J BIOL CHEM, (1982) 257 (8), 4610-4617.
     CODEN: JBCHA3. ISSN: 0021-9258.
FS   BA; OLD
LA   English

L13  ANSWER 6 OF 11  BIOSIS  COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN   1982:164605  BIOSIS
DN   BA73:24589
TI   RESCUE OF EMBRYONIC CELLS HOMO ZYGOUS FOR A LETHAL HAPLOTYPE OF THE T-T
     COMPLEX T-W-1 2.
AU   AXELROD H R; ARTZT K; BENNETT D
CS   LABORATORY OF DEVELOPMENTAL GENETICS, SLOAN-KETTERING INST. FOR CANCER
     RESEARCH, NEW YORK, N.Y. 10021.
SO   DEV BIOL, (1981) 86 (2), 419-425.
     CODEN: DEBIAO. ISSN: 0012-1606.
FS   BA; OLD
LA   English

L13  ANSWER 7 OF 11  BIOSIS  COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN   1981:144135  BIOSIS
DN   BA71:14127
TI   IDENTIFICATION OF POLIOVIRUS POLY PEPTIDE P-63 AS A SOLUBLE RNA DEPENDENT
     RNA POLYMERASE.
AU   VAN DYKE T A; FLANEGAN J B
CS   DEP. IMMUNOLOGY, MED. MICROBIOL., COLL. MED., UNIV. FLORIDA, GAINESVILLE,
     FLORIDA 32610.
SO   J VIROL, (1980) 35 (3), 732-740.
     CODEN: JOVIAM. ISSN: 0022-538X.
FS   BA; OLD
LA   English

L13  ANSWER 8 OF 11  BIOSIS  COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN   1979:206340  BIOSIS
DN   BA68:8844
TI   POLIOVIRUS POLY URIDYLIC-ACID POLYMERASE AND RNA REPLICASE HAVE THE SAME
     VIRAL POLY PEPTIDE.
AU   FLANEGAN J B; BALTIMORE D
CS   DEP. BIOL., MASS. INST. TECHNOL., CAMBRIDGE, MASS. 02139, USA.
SO   J VIROL, (1979) 29 (1), 352-360.
     CODEN: JOVIAM. ISSN: 0022-538X.
FS   BA; OLD
LA   English
```

L13 ANSWER 9 OF 11 CAPLUS COPYRIGHT 2002 ACS
AN 1982:453050 CAPLUS
DN 97:53050
TI A gene product of the mouse t complex with chemical properties of a cell surface-associated component of the extracellular matrix
AU Silver, Lee M.; White, Mary
CS Cold Spring Harbor Lab., Cold Spring Harbor, NY, 11724, USA
SO Dev. Biol. (1982), 91(2), 423-30
CODEN: DEBIAO; ISSN: 0012-1606
DT Journal
LA English

L13 ANSWER 10 OF 11 USPATFULL
AN 96:5704 USPATFULL
TI Nucleotide sequences useful as type specific probes, PCR primers and LCR probes for the amplification and detection of human papilloma virus, and related kits and methods
IN Bouma, Stanley R., Mundelein, IL, United States
Joseph, Jeffrey L., Cherry Hill, NJ, United States
Marshall, Ronald L., Zion, IL, United States
Laffler, Thomas G., Libertyville, IL, United States
PA Abbott Laboratories, Abbott Park, IL, United States (U.S. corporation)
PI US 5484699 19960116
AI US 1994-316293 19940930 (8)
RLI Continuation of Ser. No. US 1992-965665, filed on 22 Oct 1992, now abandoned which is a continuation-in-part of Ser. No. US 1990-589948, filed on 28 Sep 1990, now abandoned And a continuation-in-part of Ser. No. US 1990-590105, filed on 28 Sep 1990, now abandoned And a continuation-in-part of Ser. No. US 1990-590253, filed on 28 Sep 1990, now abandoned
DT Utility
FS Granted
LN.CNT 1679
INCL INCLM: 435/005.000
INCLS: 536/023.100; 536/023.720
NCL NCLM: 435/005.000
NCLS: 536/023.100; 536/023.720
IC [6]
ICM: C12Q001-70
ICS: C07H021-02; C07H021-04
EXF 435/5; 435/6; 935/77; 935/78; 536/23.1; 536/23.72; 536/24.3
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 11 OF 11 USPATFULL
AN 95:5769 USPATFULL
TI Use of IL-4 to treat solid tumors
IN Plunkett, Marian L., Edison, NJ, United States
Catino, Joseph J., Lebanon, NJ, United States
PA Schering-Plough Corporation, Kenilworth, NJ, United States (U.S. corporation)
PI US 5382427 19950117
WO 9204044 19920319
AI US 1993-984414 19930304 (7)
WO 1991-US6126 19910903
19930304 PCT 371 date
19930304 PCT 102(e) date
RLI Continuation-in-part of Ser. No. US 1990-578968, filed on 6 Sep 1990, now abandoned
DT Utility
FS Granted
LN.CNT 488
INCL INCLM: 424/085.200
INCLS: 424/085.100
NCL NCLM: 424/085.200
NCLS: 424/085.100
IC [6]
ICM: A61K037-02
ICS: C07K013-00
EXF 424/85.1; 424/85.2
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 10:35:21 ON 11 APR 2002)

FILE 'MEDLINE, CANCERLIT, EMBASE, BIOSIS, CAPLUS, USPATFULL' ENTERED AT 10:36:25 ON 11 APR 2002
L1 4008 S P63 OR P63 GENE
L2 3824815 S CANCER? OR MALIGNANT? OR NEOPLASM?
L3 325 S L1 AND L2
L4 1304621 S CARCINOMA?
L5 128 S L4 AND L3
L6 4957279 S DIAGNOS?
L7 39 S L5 AND L6
L8 2114047 S ANTIBOD?
L9 273 S L1 AND L8
L10 160 S L9 NOT PY=>1999
L11 4 S L10 AND L4
L12 171 S L4 AND L1
L13 11 S L12 NOT PY=>1999

=> s l3 not py=>1999
L14 24 L3 NOT PY=>1999

=> d l14 1-24

L14 ANSWER 1 OF 24 MEDLINE
AN 1998314849 MEDLINE
DN 98314849 PubMed ID: 9652741
TI Allelic loss analysis of gamma-ray-induced mouse thymic lymphomas: two candidate tumor suppressor gene loci on chromosomes 12 and 16.
AU Matsumoto Y; Kosugi S; Shinbo T; Chou D; Ohashi M; Wakabayashi Y; Sakai K; Okumoto M; Mori N; Aizawa S; Niwa O; Kominami R
CS Department of Biochemistry, Niigata University School of Medicine, Asahimachi, Japan.
SO ONCOGENE, (1998 May 28) 16 (21) 2747-54.
Journal code: ONC; 8711562. ISSN: 0950-9232.
CY ENGLAND: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199807
ED Entered STN: 19980811
Last Updated on STN: 19980811
Entered Medline: 19980728

L14 ANSWER 2 OF 24 MEDLINE
AN 97184593 MEDLINE
DN 97184593 PubMed ID: 9032395
TI Binding sites for adeno-associated virus Rep proteins within the human genome.
AU Wonderling R S; Owens R A
CS Laboratory of Molecular and Cellular Biology, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland 20892, USA.
SO JOURNAL OF VIROLOGY, (1997 Mar) 71 (3) 2528-34.
Journal code: KCV; 0113724. ISSN: 0022-538X.

CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
OS GENBANK-L13744; GENBANK-L22078; GENBANK-M11038; GENBANK-M60756; GENBANK-M69237; GENBANK-Z50150
EM 199703
ED Entered STN: 19970327
Last Updated on STN: 19970327
Entered Medline: 19970318

L14 ANSWER 3 OF 24 CANCERLIT
AN 1998314849 CANCERLIT
DN 98314849
TI Allelic loss analysis of gamma-ray-induced mouse thymic lymphomas: two candidate tumor suppressor gene loci on chromosomes 12 and 16.
AU Matsumoto Y; Kosugi S; Shinbo T; Chou D; Ohashi M; Wakabayashi Y; Sakai K; Okumoto M; Mori N; Aizawa S; Niwa O; Kominami R
CS Department of Biochemistry, Niigata University School of Medicine, Asahimachi, Japan.
SO ONCOGENE, (1998). Vol. 16, No. 21, pp. 2747-54.
Journal code: ONC. ISSN: 0950-9232.
DT Journal; Article; (JOURNAL ARTICLE)
FS MEDL; L; Priority Journals; Cancer Journals
LA English
OS MEDLINE 98314849
EM 199809

L14 ANSWER 4 OF 24 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
AN 97383551 EMBASE
DN 1997383551
TI Activation of adenomatous polyposis coli (APC) gene expression by the DNA-alkylating agent N-methyl-N'-nitro-N-nitrosoguanidine requires p53.
AU Narayan S.; Jaiswal A.S.
CS S. Narayan, Sealy Center for Oncology/Hematology, 9.104 Medical Research Bldg., University of Texas Medical Branch, 301 University Blvd., Galveston, TX 77555-1048, United States. snarayan@mspo7.med.utmb.edu
SO Journal of Biological Chemistry, (1997) 272/49 (30619-30622).
Refs: 34
ISSN: 0021-9258 CODEN: JBCHA3
CY United States
DT Journal; Article
FS 016 Cancer
029 Clinical Biochemistry
LA English
SL English

L14 ANSWER 5 OF 24 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
AN 97054860 EMBASE
DN 1997054860
TI Binding sites for adeno-associated virus Rep proteins within the human genome.
AU Wonderling R.S.; Owens R.A.
CS R.A. Owens, Lab. of Molecular/Cellular Biology, NIDDK, National Institutes of Health, 8 Center Dr., Bethesda, MD 20892-0840, United States. roland@bdg8.niddk.nih.gov
SO Journal of Virology, (1997) 71/3 (2528-2534).
Refs: 56
ISSN: 0022-538X CODEN: JOVIAM
CY United States
DT Journal; Article
FS 004 Microbiology
LA English
SL English

L14 ANSWER 6 OF 24 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
AN 97005436 EMBASE
DN 1997005436
TI Deletions and loss of expression of P16(INK4a) and P21(Waf1) genes are associated with aggressive variants of mantle cell lymphomas.
AU Pinyal M.; Hernandez L.; Cazorla M.; Balbin M.; Jares P.; Fernandez P.L.; Montserrat E.; Cardesa A.; Lopez-Otin C.; Campo E.
CS Dr. E. Campo, Laboratory of Anatomic Pathology, Hospital Clinic Provincial, Villarroel 170, 08036-Barcelona, Spain
SO Blood, (1997) 89/1 (272-280).
Refs: 57
ISSN: 0006-4971 CODEN: BLOOAW
CY United States
DT Journal; Article
FS 016 Cancer
022 Human Genetics
025 Hematology
LA English
SL English

L14 ANSWER 7 OF 24 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
AN 96110930 EMBASE
DN 1996110930
TI Mutations of the p53 gene in the stool of patients with resectable colorectal **cancer**.
AU Eguchi S.; Kohara N.; Komuta K.; Kanematsu T.
CS Department of Surgery II, Nagasaki Univ. School of Medicine, 1-7-1 Sakamoto,Nagasaki 852, Japan
SO Cancer, (1996) 77/8 SUPPL. (1707-1710).
ISSN: 0008-543X CODEN: CANCAR
CY United States
DT Journal; Conference Article
FS 016 Cancer
022 Human Genetics
048 Gastroenterology
LA English
SL English

L14 ANSWER 8 OF 24 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
AN 95236528 EMBASE
DN 1995236528
TI Alteration of c-erbB-2 and p53 product expressions in prostatic **cancer** before and after the development of androgen-independency.
AU Ishibashi Y.; Fukuoka H.; Fujinami K.; Sekiguchi Y.; Sakanishi S.
CS Department of Urology, Yokohama Minami Kyosai Hospital,Yokohama, Japan
SO Nishinihon Journal of Urology, (1995) 57/7 (802-805).
ISSN: 0029-0726 CODEN: NHJUAR
CY Japan
DT Journal; Article
FS 009 Surgery
016 Cancer
028 Urology and Nephrology
LA English
SL English; Japanese

L14 ANSWER 9 OF 24 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
AN 94048929 EMBASE
DN 1994048929
TI Genomic loci of human mitogen-activated protein kinases.
AU Li L.; Wysk M.; Gonzalez F.A.; Davis R.J.
CS Howard Hughes Medical Institute, Biochemistry and Molecular Biology, Univ Massachusetts Medical School,Worcester, MA 01605, United States
SO Oncogene, (1994) 9/2 (647-649).

ISSN: 0950-9232 CODEN: ONCNES
CY United Kingdom
DT Journal; Article
FS 022 Human Genetics
LA English
SL English

L14 ANSWER 10 OF 24 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
AN 91349918 EMBASE
DN 1991349918
TI Research reports. An additional homolog of the fission yeast cdc25+ gene occurs in humans and is highly expressed in some **cancer** cells.
AU Nagata A.; Igarashi M.; Jinno S.; Suto K.; Okayama H.
CS Department of Molecular Genetics, Research Institute for Microbial Diseases, Osaka University, 3-1 Yamadaoka, Suita, Osaka 565, Japan
SO New Biologist, (1991) 3/10 (959-965).
ISSN: 1043-4674 CODEN: NEBIE2
CY United States
DT Journal; Article
FS 016 Cancer
022 Human Genetics
LA English
SL English

L14 ANSWER 11 OF 24 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 1997:126815 BIOSIS
DN PREV199799413828
TI Binding sites for adeno-associated virus rep proteins within the human genome.
AU Wonderling, Ramani S.; Owens, Roland A. (1)
CS (1) Lab. Molecular and Cellular Biol., NIDDK, Natl. Inst. Health, Build. 8, Room 309, 8 Center Dr., MSC 0840, Bethesda, MD 20892-0840 USA
SO Journal of Virology, (1997) Vol. 71, No. 3, pp. 2528-2534.
ISSN: 0022-538X.
DT Article
LA English

L14 ANSWER 12 OF 24 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 1995:269151 BIOSIS
DN PREV199598283451
TI P53 gene mutation and expression in naevi and melanomas.
AU Sparrow, L. E.; Soong, R.; Dawkins, H. J. S. (1); Iacopetta, B. J.; Heenan, P. J.
CS (1) Mol. Oncol. Lab., Dep. Pathol., Univ. Western Australia, Queen Elizabeth II Med. Cent., Nedlands 6009, W. Australia
SO Melanoma Research, (1995) Vol. 5, No. 2, pp. 93-100.
ISSN: 0960-8931.
DT Article
LA English

L14 ANSWER 13 OF 24 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 1994:532148 BIOSIS
DN PREV199497545148
TI Mutation of p53 gene in human **cancers** of the esophagus and gastric cardia.
AU Li, Huan-Chuan; Lu, Shi-Xin
CS Cancer Inst., Chinese Academy Med. Sci. Peking Union Med. College, Beijing 100021 China
SO Zhonghua Zhongliu Zazhi, (1994) Vol. 16, No. 3, pp. 172-176.
ISSN: 0253-3758.
DT Article
LA Chinese
SL Chinese; English

L14 ANSWER 14 OF 24 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 1994:288764 BIOSIS
DN PREV199497301764
TI Differential expression of **p63** in human breast **cancer**.
AU Pujol, P. (1); Allred, D. C.; Osborne, C. K.; Haurie, H.-P.; Fuqua, S. A. W.
CS (1) Univ. Tex. Health Sci. Cent., San Antonio, TX 78284 USA
SO Proceedings of the American Association for Cancer Research Annual Meeting, (1994) Vol. 35, No. 0, pp. 165.
Meeting Info.: 85th Annual Meeting of the American Association for Cancer Research San Francisco, California, USA April 10-13, 1994
ISSN: 0197-016X.
DT Conference
LA English

L14 ANSWER 15 OF 24 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 1994:129565 BIOSIS
DN PREV199497142565
TI Genomic loci of human mitogen-activated protein kinases.
AU Li, Li; Wysk, Mark; Gonzalez, Fernando A.; Davis, Roger J. (1)
CS (1) Howard Hughes Med. Inst., Univ. Mass. Med. Sch., Worcester, MA 01605 USA
SO Oncogene, (1994) Vol. 9, No. 2, pp. 647-649.
ISSN: 0950-9232.
DT Article
LA English

L14 ANSWER 16 OF 24 CAPLUS COPYRIGHT 2002 ACS
AN 1997:299815 CAPLUS
DN 127:1407
TI Molecular cloning of a novel human gene encoding a 63-kDa protein and its sublocalization within the 11q13 locus
AU Perelman, Boris; Dafni, Naomi; Naiman, Tova; Eli, Dalia; Yaakov, Miri; Feng, Teresa L. Yang; Sinha, Srish; Weber, Gunther; Khodaei, Shideh; Sancar, Aziz; Dotan, Iris; Canaani, Dan
CS Department of Biochemistry, Tel Aviv University, Ramat Aviv, 69978, Israel
SO Genomics (1997), 41(3), 397-405
CODEN: GNMCEP; ISSN: 0888-7543
PB Academic
DT Journal
LA English

L14 ANSWER 17 OF 24 CAPLUS COPYRIGHT 2002 ACS
AN 1997:122080 CAPLUS
DN 126:167360
TI Binding sites for adeno-associated virus Rep proteins within the human genome
AU Wonderling, Ramani S.; Owens, Roland A.
CS Laboratory Molecular and Cellular Biology, National Institute Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 20892, USA
SO J. Virol. (1997), 71(3), 2528-2534
CODEN: JOVIAM; ISSN: 0022-538X
PB American Society for Microbiology
DT Journal
LA English

L14 ANSWER 18 OF 24 CAPLUS COPYRIGHT 2002 ACS
AN 1995:903102 CAPLUS
DN 123:357587
TI Reactions of the Tetrachlorobis(imidazole)ruthenium(III) and Pentachloro(imidazole)ruthenium(III) Anions with Imidazole and N6,N6-Dimethyladenine
AU Anderson, Craig; Beauchamp, Andre L.
CS Departement de Chimie, Universite de Montreal, Montreal, PQ, H3C 3J7, Can.

SO Inorg. Chem. (1995), 34(24), 6065-73
CODEN: INOCAJ; ISSN: 0020-1669
DT Journal
LA English

L14 ANSWER 19 OF 24 CAPLUS COPYRIGHT 2002 ACS
AN 1995:688168 CAPLUS
DN 123:140517
TI Genetic alterations cooperate with v-Ha-ras to accelerate multistage carcinogenesis in TG.AC transgenic mouse skin
AU Owens, David M.; Spalding, Judson, W.; Tennant, Raymond W.; Smart, Robert C.
CS Dep. of Toxicology, North Carolina State Univ., Raleigh, NC, 27695, USA
SO Cancer Res. (1995), 55(14), 3171-8
CODEN: CNREA8; ISSN: 0008-5472
DT Journal
LA English

L14 ANSWER 20 OF 24 USPATFULL
AN 1998:147208 USPATFULL
TI Topologically segregated, encoded solid phase libraries
IN Lebl, Michal, Oro Valley, AZ, United States
Lam, Kit S., Tucson, AZ, United States
Salmon, Sydney E., Tucson, AZ, United States
Krchnak, Victor, Oro Valley, AZ, United States
Sepetov, Nikolai, Oro Valley, AZ, United States
Kocis, Peter, Oro Valley, AZ, United States
PA Selectide Corporation, DE, United States (U.S. corporation)
PI US 5840485 19981124
AI US 1994-249830 19940526 (8)
RLI Continuation-in-part of Ser. No. US 1993-68327, filed on 27 May 1993, now abandoned
DT Utility
FS Granted
LN.CNT 4549
INCL INCLM: 435/006.000
INCLS: 435/007.100; 530/300.000; 530/323.000; 436/518.000; 536/023.100; 935/077.000; 935/078.000
NCL NCLM: 435/006.000
NCLS: 435/007.100; 435/DIG.022; 435/DIG.034; 435/DIG.035; 435/DIG.038; 436/518.000; 530/300.000; 530/323.000; 536/023.100
IC [6]
ICM: C12Q001-68
ICS: G01N033-53; C07K017-02; C07H021-04
EXF 435/6; 435/7.1; 436/518; 530/333; 530/334; 530/300; 530/345; 530/323; 530/812; 536/23.1; 536/24.3
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 21 OF 24 USPATFULL
AN 1998:30906 USPATFULL
TI Isolated nucleic acid molecule which codes for a 32 kDa protein having 11-cis retinol dehydrogenase activity, and which associates with **p63**, a portion of a retinol binding protein receptor
IN Simon, Andras, Stockholm, Sweden
Hellman, Ulf, Upsala, Sweden
Wernstedt, Christer, Upsala, Sweden
Eriksson, Ulf, Stockholm, Sweden
PA Ludwig Institute for Cancer Research, New York, NY, United States (U.S. corporation)
PI US 5731195 19980324
AI US 1995-375962 19950120 (8)
RLI Continuation-in-part of Ser. No. US 1994-258418, filed on 10 Jun 1994, now abandoned
DT Utility
FS Granted
LN.CNT 966
INCL INCLM: 435/252.300
INCLS: 435/069.100; 435/320.100; 536/023.500; 536/024.310
NCL NCLM: 435/252.300
NCLS: 435/069.100; 435/320.100; 536/023.500; 536/024.310
IC [6]
ICM: C12N015-12
ICS: C12N005-10
EXF 435/69.1; 435/252.3; 435/320.1; 536/23.5; 536/24.31
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 22 OF 24 USPATFULL
AN 97:89071 USPATFULL
TI Nucleoside 5'-methylene phosphonates
IN Buhr, Chris, Daly City, CA, United States
Matteucci, Mark, Burlingame, CA, United States
Bischofberger, Norbert W., San Carlos, CA, United States
Froehler, Brian, Belmont, CA, United States
PA Gilead Sciences, Inc., Foster City, CA, United States (U.S. corporation)
PI US 5672697 19970930
AI US 1991-652978 19910208 (7)
DT Utility
FS Granted
LN.CNT 1452
INCL INCLM: 536/026.700
INCLS: 536/026.800
NCL NCLM: 536/026.700
NCLS: 536/026.800
IC [6]
ICM: C07H019-073
ICS: C07H019-173
EXF 536/27-29; 536/28.2; 536/27.81; 536/28.5; 536/28.53; 536/28.55; 536/26.7; 536/26.8; 514/46; 514/47-48; 514/51
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 23 OF 24 USPATFULL
AN 96:5704 USPATFULL
TI Nucleotide sequences useful as type specific probes, PCR primers and LCR probes for the amplification and detection of human papilloma virus, and related kits and methods
IN Bouma, Stanley R., Mundelein, IL, United States
Joseph, Jeffrey L., Cherry Hill, NJ, United States
Marshall, Ronald L., Zion, IL, United States
Laffler, Thomas G., Libertyville, IL, United States
PA Abbott Laboratories, Abbott Park, IL, United States (U.S. corporation)
PI US 5484699 19960116
AI US 1994-316293 19940930 (8)
RLI Continuation of Ser. No. US 1992-965665, filed on 22 Oct 1992, now abandoned which is a continuation-in-part of Ser. No. US 1990-589948, filed on 28 Sep 1990, now abandoned And a continuation-in-part of Ser. No. US 1990-590105, filed on 28 Sep 1990, now abandoned And a continuation-in-part of Ser. No. US 1990-590253, filed on 28 Sep 1990, now abandoned
DT Utility
FS Granted
LN.CNT 1679
INCL INCLM: 435/005.000
INCLS: 536/023.100; 536/023.720
NCL NCLM: 435/005.000
NCLS: 536/023.100; 536/023.720
IC [6]
ICM: C12Q001-70
ICS: C07H021-02; C07H021-04

=> d 2 all

L4 ANSWER 2 OF 7 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 1994:288764 BIOSIS
DN PREV199497301764
TI Differential expression of **p63** in human breast **cancer**.
AU Pujol, P. (1); Allred, D. C.; Osborne, C. K.; Haurie, H.-P.; Fuqua, S. A. W.
CS (1) Univ. Tex. Health Sci. Cent., San Antonio, TX 78284 USA
SO Proceedings of the American Association for Cancer Research Annual Meeting, (1994) Vol. 35, No. 0, pp. 165.
Meeting Info.: 85th Annual Meeting of the American Association for Cancer Research San Francisco, California, USA April 10-13, 1994
ISSN: 0197-016X.
DT Conference
LA English
CC Genetics and Cytogenetics - Human *03508
Reproductive System - Pathology *16506
Neoplasms and Neoplastic Agents - Carcinogens and Carcinogenesis *24007
BC Hominidae *86215
IT Major Concepts
Genetics; Oncology (Human Medicine, Medical Sciences); Reproductive System (Reproduction)
IT Miscellaneous Descriptors
CARCINOGENESIS; MEETING ABSTRACT
ORGN Super Taxa
Hominidae: Primates, Mammalia, Vertebrata, Chordata, Animalia
ORGN Organism Name
Hominidae (Hominidae)
ORGN Organism Superterms
animals; chordates; humans; mammals; primates; vertebrates

L4 ANSWER 3 OF 7 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
AN 96110930 EMBASE
DN 1996110930
TI Mutations of the p53 gene in the stool of patients with resectable colorectal **cancer**.
AU Eguchi S.; Kohara N.; Komuta K.; Kanematsu T.
CS Department of Surgery II, Nagasaki Univ. School of Medicine, 1-7-1 Sakamoto,Nagasaki 852, Japan
SO Cancer, (1996) 77/8 SUPPL. (1707-1710).
ISSN: 0008-543X CODEN: CANCAR
CY United States
DT Journal; Conference Article
FS 016 Cancer
022 Human Genetics
048 Gastroenterology
LA English
SL English
AB BACKGROUND. This study was undertaken to evaluate whether genetic analysis in the stool can be useful for detecting malignant tumors in the colon and rectum. We searched for the possible presence of mutations in the p53 gene in the stool of patients with resectable colorectal **cancer**. Alterations in the p53 gene are the most frequent among mutant genes related to colorectal **cancer**. METHODS. Surgically resected tumor specimens and stool samples from 25 patients with colorectal **cancer** were examined for mutations of exons 5-8 of the p53 gene by polymerase chain reaction single-strand conformation polymorphism (PCR-SSCP). Results were compared with those achieved by fecal occult blood testing. RESULTS. Mutations of the p53 gene were found in the tumor tissues in 11 of 25 patients (44%). Of these 11 patients, 7 (64%) had evidence of alterations in the **p63** gene within the stool. Of five patients who were negative for fecal occult blood testing, **p63** mutations in the stool were evident in three patients. CONCLUSIONS. This method of stool DNA analysis for tumor-specific mutations is expected to have a wide application in clinical screening for colorectal **cancer**.
CT Medical Descriptors:
***colorectal cancer: DI, diagnosis**
***colorectal cancer: SU, surgery**
*feces
*gene
adult
aged
clinical article
conference paper
female
gene mutation
human
human tissue
male
polymerase chain reaction
priority journal
single strand conformation polymorphism
spectrophotometry
Drug Descriptors:
*dna: EC, endogenous compound
*protein p53: EC, endogenous compound
RN (dna) 9007-49-2

=> d 4 all

L4 ANSWER 4 OF 7 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
AN 95236528 EMBASE
DN 1995236528
TI Alteration of c-erbB-2 and p53 product expressions in prostatic **cancer** before and after the development of androgen-independency.
AU Ishibashi Y.; Fukuoka H.; Fujinami K.; Sekiguchi Y.; Sakanishi S.
CS Department of Urology, Yokohama Minami Kyosai Hospital,Yokohama, Japan
SO Nishinihon Journal of Urology, (1995) 57/7 (802-805).
ISSN: 0029-0726 CODEN: NHJUAR
CY Japan
DT Journal; Article
FS 009 Surgery
016 Cancer
028 Urology and Nephrology
LA English
SL English; Japanese
AB We examined whether there is any alteration of c-erbB-2 and p53 products in prostatic **cancer** specimens from the same patient before treatment and after reactivation. No staining was found for the c-erbB-2 product in any specimens taken before treatment and after reactivation from 9 patients. As for the p53 product, however, 2 specimens showed positive staining after reactivation, although all 9 specimens had been negative before treatment. However, the positive rate was only 22.2% (2/9). The median of intervals of these 2 cases between the beginning of reactivation and post reactivation biopsy was twice as long as that of the remaining 7 cases with unchanged negative staining. This fact suggests that these 2 patients were much closer to being at a late stage at the time of post-reactivation biopsy. Our result is consistent with reports that **p63** is correlated with the later stage of progression in prostatic **cancer**.
CT Medical Descriptors:
***prostate cancer: DI, diagnosis**
adult
aged
article
clinical article
gene expression
human
male
oncogene
prostate biopsy
protein determination
transurethral resection
Drug Descriptors:
*oncoprotein: EC, endogenous compound
*protein p53: EC, endogenous compound

=> d 1, 2, 4, 7 all

L23 ANSWER 1 OF 8 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 1997:65556 BIOSIS
DN PREV199799364759
TI Tumor suppressor gene alteration in adult acute lymphoblastic leukemia (ALL). Analysis of retinoblastoma (Rb) and **p53** gene expression in lymphoblasts of patients with de novo, relapsed, or refractory ALL treated in Southwest Oncology Group studies.
AU Tsai, T.; Davalath, S.; Rankin, C.; Radich, J. P.; Head, D.; Appelbaum, F. R.; Boldt, D. H. (1)
CS (1) Med. Hematology, Univ. Texas Health Science Cent., 7703 Floyd Curl Drive, San Antonio, TX 78284-7880 USA
SO Leukemia (Basingstoke), (1996) Vol. 10, No. 12, pp. 1901-1910. ISSN: 0887-6924.
DT Article
LA English
AB To examine the impact of inactivation of tumor suppressor genes on outcome in adult ALL, we compared two groups of patients registered to SWOG treatment protocols for loss of the Rb gone product and **p53** overexpression: (1) 89 patients with de novo ALL, and (2) 26 patients with relapsed/refractory ALL. The groups were comparable with respect to age, sex, and race. Cell lysates (gtoreq 80% blasts) were analyzed by immunoblotting which enabled detection of Rb or **p53** proteins in as little as 1 mu-g of lysate. Loss of Rb expression (pRbneg) was found in 54/85 (64%) de novo and 11/19 (58%) relapsed patients (P = 0.79). Overexpression of **p53** (p53abn), indicative of **p63** point **mutations**, was found in 16/75 (21%) de novo and 8/19 (42%) relapsed patients (P = 0.08). Using a nonisotopic RNase cleavage assay, **p53** point **mutations** in exons 5-9 were confirmed in 14/23 (61%) p53abn specimens. For the de novo ALL group, patients with normal Rb protein had higher WBC and higher peripheral blast and lymphocyte counts. Otherwise neither abnormal Rb or **p53** expression correlated with any of a large panel of clinical and laboratory variables including FAB class, blast lineage, expression of myeloid antigens or CD34, and presence of the Ph1 chromosome or BCR-ABL. Analyses of treatment outcomes demonstrated no significant impact of Rb or **p53** status alone on CR rates, relapse-free or overall survival. An identical percentage (11%) of both de novo and relapsed/refractory patients had concurrent abnormalities of both Rb and **p53** expression (pRbneg/p53abn). The survival curve of these patients suggests an increased rate of early death, but the number of patients in this group was small. Summarizing, (1) loss of Rb expression is common in adult ALL; (2) overexpression of **p53** may be more frequent in relapsed/refractory than de novo adult ALL; and (3) although Rb or **p53** alteration alone are not strong Independent predictors of outcome, their concurrent expression may predict a poor response to therapy.
CC Genetics and Cytogenetics - Human *03508
Pathology, General and Miscellaneous - Therapy *12512
Blood, Blood-Forming Organs and Body Fluids - Blood, Lymphatic and Reticuloendothelial Pathologies *15006
Blood, Blood-Forming Organs and Body Fluids - Lymphatic Tissue and Reticuloendothelial System *15008
Neoplasms and Neoplastic Agents - Pathology; Clinical Aspects; Systemic Effects *24004
Neoplasms and Neoplastic Agents - Biochemistry *24006
Neoplasms and Neoplastic Agents - Therapeutic Agents; Therapy *24008
Neoplasms and Neoplastic Agents - Blood and Reticuloendothelial Neoplasms *24010
BC Hominidae *86215
IT Major Concepts
Blood and Lymphatics (Transport and Circulation); Genetics; Hematology (Human Medicine, Medical Sciences); Oncology (Human Medicine, Medical

Sciences); Pathology
IT Miscellaneous Descriptors
ADULT ACUTE LYMPHOBLASTIC LEUKEMIA; BLOOD AND LYMPHATIC DISEASE; DE NOVO; GENE EXPRESSION; MOLECULAR GENETICS; NEOPLASTIC DISEASE; PATIENT; **P53** GENE; REFRACTORY; RELAPSED; RETINOBLASTOMA GENE; SOUTHWEST ONCOLOGY GROUP STUDY; TREATMENT RESPONSE; TUMOR BIOLOGY; TUMOR SUPPRESSOR GENE ALTERATION
ORGN Super Taxa
Hominidae: Primates, Mammalia, Vertebrata, Chordata, Animalia
ORGN Organism Name
human (Hominidae)
ORGN Organism Superterms
animals; chordates; humans; mammals; primates; vertebrates

L23 ANSWER 2 OF 8 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 1995:269151 BIOSIS
DN PREV199598283451
TI **P53** gene **mutation** and expression in naevi and melanomas.
AU Sparrow, L. E.; Soong, R.; Dawkins, H. J. S. (1); Iacopetta, B. J.; Heenan, P. J.
CS (1) Mol. Oncol. Lab., Dep. Pathol., Univ. Western Australia, Queen Elizabeth II Med. Cent., Nedlands 6009, W. Australia
SO Melanoma Research, (1995) Vol. 5, No. 2, pp. 93-100.
ISSN: 0960-8931.
DT Article
LA English
AB **Mutations** of the **p53** tumour suppressor gene are common to many human malignancies. Although increased **p63** expression has been observed in cutaneous malignant melanoma, **mutations** of the **p53** gene appear to be infrequent. We examined 140 benign and malignant paraffin-embedded melanocytic lesions for **p53** protein expression by immunohistochemistry, using the monoclonal anti-**p53** antibody DO-7 and a microwave method of antigen retrieval. Fifteen naevi and 25 melanomas were further analysed for **p53 mutations** within exons 5-8 of the **p53** gene. DNA was extracted from paraffin sections and screening for **mutations** was carried out using PCR-SSCP. We demonstrated **p53** protein expression in 33% of naevi (17 out of 51), 35% of primary melanomas (20 out of 58), and 70% of metastatic lesions (15 out of 21). **p53** expression in benign lesions was weaker than in malignant lesions in intensity and percentage of cells staining. **p53** protein expression in melanomas increased in intensity and percentage of cells staining with tumour progression. In 25% (three out of 12) of metastatic melanomas **p53 mutations** were detected by PCR-SSCP and increased expression of **p53** protein was observed in these tumours. **p53** gene **mutations** were not detected in any benign melanocytic lesions. We demonstrate that antigen retrieval techniques increase **p53** immunoreactivity in paraffin embedded melanocytic tissues. **p53** protein expression in melanomas increases with depth of tumour invasion. melanoma, other mechanisms are proposed to influence **p53** protein expression in melanocytic lesions.
CC Genetics and Cytogenetics - Human *03508
Biochemical Studies - Nucleic Acids, Purines and Pyrimidines 10062
Integumentary System - Pathology *18506
Neoplasms and Neoplastic Agents - Biochemistry *24006
Neoplasms and Neoplastic Agents - Carcinogens and Carcinogenesis *24007
Immunology and Immunochemistry - General; Methods *34502
BC Hominidae *86215
IT Major Concepts
Dermatology (Human Medicine, Medical Sciences); Genetics; Oncology (Human Medicine, Medical Sciences)
IT Miscellaneous Descriptors
DNA; IMMUNOHISTOCHEMISTRY; ONCOGENESIS; TUMOR SUPPRESSOR GENE

ORGN Super Taxa
Hominidae: Primates, Mammalia, Vertebrata, Chordata, Animalia
ORGN Organism Name
human (Hominidae)
ORGN Organism Superterms
animals; chordates; humans; mammals; primates; vertebrates

L23 ANSWER 4 OF 8 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 1994:451861 BIOSIS
DN PREV199497464861
TI **P53** Protein accumulation in lung carcinomas of patients exposed to asbestos and tobacco smoke.
AU Nuorva, Kyosti; Makitaro, Riitta; Huhti, Esko; Kamel, Dia; Vahakangas, Kirsi; Bloigu, Risto; Soini, Ylermi; Paakko, Paavo (1)
CS (1) Dep. Pathol., Univ. Oulu, Kajaanintie 52D, 90220 Oulu Finland
SO American Journal of Respiratory and Critical Care Medicine, (1994) Vol. 150, No. 2, pp. 528-533.
DT Article
LA English
AB Primary lung carcinomas often carry **mutations** in the **p53** tumor suppressor gene. Most of these **mutations** alter the conformation of the **p53** protein into a more stable phenotype that makes it immunohistochemically detectable. Asbestos is a carcinogen that can cause deletions in chromosomes and possibly also gene **mutations**. In this study we examined 70 primary lung carcinomas for **p53** protein accumulation using a polyclonal antihuman **p53** antibody, CM-1. Patients were interviewed about their occupational and smoking history and classified according to their anamnestical asbestos exposure. Presence of asbestos bodies (AB) was evaluated from histologic samples of peripheral nontumorous lung tissue using both 5-mu-m-thick sections stained with Perls' iron and 30-mu-m-thick unstained sections. Abnormal accumulation of **p63** protein was found in 36 tumors (51%), more often in patients exposed to asbestos than in patients without exposure (67% versus 40%, p = 0.027). Significant association was also noticed between the accumulation of **p53** and the asbestos content of lung tissue: 35% of the **p53**-positive patients had more than one AB/cm-2 compared with 14% of **p53**-negative cases (p = 0.046). Patients with strongly **p53**-positive tumors were heavier smokers (57.2 +- 38.2 pack-years) than patients with **p53**-negative or lightly positive tumors (38.9 +- 19.9 pack-years) (p = 0.017). Our findings indicate that both asbestos exposure and heavy smoking can cause abnormal **p53** protein accumulation suggestive of mutated **p53**.
CC Microscopy Techniques - Histology and Histochemistry *01056
Genetics and Cytogenetics - Human *03508
Behavioral Biology - Human Behavior *07004
Biochemical Studies - General 10060
Biochemical Studies - Nucleic Acids, Purines and Pyrimidines 10062
Biochemical Studies - Proteins, Peptides and Amino Acids 10064
Metabolism - Proteins, Peptides and Amino Acids *13012
Metabolism - Nucleic Acids, Purines and Pyrimidines *13014
Respiratory System - Pathology *16006
Psychiatry - Addiction - Alcohol, Drugs, Smoking, etc. *21004
Toxicology - General; Methods and Experimental *22501
Toxicology - Environmental and Industrial Toxicology *22506
Neoplasms and Neoplastic Agents - Biochemistry *24006
Neoplasms and Neoplastic Agents - Carcinogens and Carcinogenesis *24007
Immunology and Immunochemistry - Immunopathology, Tissue Immunology *34508
Public Health: Environmental Health - Air, Water and Soil Pollution *37015
BC Hominidae *86215
IT Major Concepts
Behavior; Clinical Immunology (Human Medicine, Medical Sciences);

Genetics; Metabolism; Methods and Techniques; Oncology (Human Medicine, Medical Sciences); Pollution Assessment Control and Management; Psychiatry (Human Medicine, Medical Sciences); Pulmonary Medicine (Human Medicine, Medical Sciences); Toxicology

IT Miscellaneous Descriptors
CARCINOGEN; CHROMOSOME DELETION; GENE **MUTATION**; IMMUNOHISTOCHEMISTRY; PHENOTYPE; SMOKING; TUMOR; TUMOR SUPPRESSOR GENE

ORGN Super Taxa
Hominidae: Primates, Mammalia, Vertebrata, Chordata, Animalia

ORGN Organism Name
human (Hominidae)

ORGN Organism Superterms
animals; chordates; humans; mammals; primates; vertebrates

L23 ANSWER 7 OF 8 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
AN 96110930 EMBASE
DN 1996110930
TI **Mutations** of the **p53** gene in the stool of patients with resectable colorectal cancer.
AU Eguchi S.; Kohara N.; Komuta K.; Kanematsu T.
CS Department of Surgery II, Nagasaki Univ. School of Medicine, 1-7-1 Sakamoto,Nagasaki 852, Japan
SO Cancer, (1996) 77/8 SUPPL. (1707-1710).
ISSN: 0008-543X CODEN: CANCAR
CY United States
DT Journal; Conference Article
FS 016 Cancer
022 Human Genetics
048 Gastroenterology
LA English
SL English
AB BACKGROUND. This study was undertaken to evaluate whether genetic analysis in the stool can be useful for detecting malignant tumors in the colon and rectum. We searched for the possible presence of **mutations** in the **p53** gene in the stool of patients with resectable colorectal cancer. Alterations in the **p53** gene are the most frequent among mutant genes related to colorectal cancer. METHODS. Surgically resected tumor specimens and stool samples from 25 patients with colorectal cancer were examined for **mutations** of exons 5-8 of the **p53** gene by polymerase chain reaction single-strand conformation polymorphism (PCR-SSCP). Results were compared with those achieved by fecal occult blood testing. RESULTS. **Mutations** of the **p53** gene were found in the tumor tissues in 11 of 25 patients (44%). Of these 11 patients, 7 (64%) had evidence of alterations in the **p63** gene within the stool. Of five patients who were negative for fecal occult blood testing, **p63 mutations** in the stool were evident in three patients. CONCLUSIONS. This method of stool DNA analysis for tumor-specific **mutations** is expected to have a wide application in clinical screening for colorectal cancer.
CT Medical Descriptors:
*colorectal cancer: DI, diagnosis
*colorectal cancer: SU, surgery
*feces
*gene
adult
aged
clinical article
conference paper
female
gene mutation
human
human tissue
male
polymerase chain reaction

priority journal
single strand conformation polymorphism
spectrophotometry
Drug Descriptors:
*dna: EC, endogenous compound
***protein p53: EC, endogenous compound**
RN (dna) 9007-49-2

=>

=> d l14 14

L14 ANSWER 14 OF 24 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 1994:298764 BIOSIS
DN PREV199497301764
TI Differential expression of **p63** in human breast **cancer**.
AU Pujol, P. (1); Allred, D. C.; Osborne, C. K.; Haurie, H.-P.; Fuqua, S. A. W.
CS (1) Univ. Tex. Health Sci. Cent., San Antonio, TX 78284 USA
SO Proceedings of the American Association for Cancer Research Annual Meeting, (1994) Vol. 35, No. 0, pp. 165.
Meeting Info.: 85th Annual Meeting of the American Association for Cancer Research San Francisco, California, USA April 10-13, 1994
ISSN: 0197-016X.
DT Conference
LA English

EXF 435/5; 435/6; 935/77; 935/78; 536/23.1; 536/23.72; 536/24.3
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 24 OF 24 USPATFULL
AN 95:5769 USPATFULL
TI Use of IL-4 to treat solid tumors
IN Plunkett, Marian L., Edison, NJ, United States
Catino, Joseph J., Lebanon, NJ, United States
PA Schering-Plough Corporation, Kenilworth, NJ, United States (U.S. corporation)
PI US 5382427 19950117
WO 9204044 19920319
AI US 1993-984414 19930304 (7)
WO 1991-US6126 19910903
19930304 PCT 371 date
19930304 PCT 102(e) date
RLI Continuation-in-part of Ser. No. US 1990-578968, filed on 6 Sep 1990, now abandoned
DT Utility
FS Granted
LN.CNT 488
INCL INCLM: 424/085.200
INCLS: 424/085.100
NCL NCLM: 424/085.200
NCLS: 424/085.100
IC [6]
ICM: A61K037-02
ICS: C07K013-00
EXF 424/85.1; 424/85.2
CAS INDEXING IS AVAILABLE FOR THIS PATENT.